Zoetis (ZTS) Stock Soaring on Earnings Beat
NEW YORK (TheStreet) -- Shares of Zoetis (ZTS) - Get Report are gaining by 5.12% to $46.42 in midday trading on Tuesday, after the veterinary medicines company reported better than expected 2015 third quarter earnings results and raised its outlook before the open this morning.
The Florham Park, NJ-based animal health medicines and vaccines producer posted adjusted earnings of 50 cents per share on revenue of $1.2 billion for the most recent quarter.
Analysts polled by Thomson Reuters had forecast for earnings of 40 cents per share on $1.18 billion in revenue for the three month period ending on September 27.
"We continued to deliver strong revenue and adjusted net income growth this quarter, based on our diverse portfolio of high-quality products and our continued discipline on costs and expenses," Zoetis CEO Juan Ramon Alaix said in a statement.
Looking to the 2015 full year the company is expecting earnings of $1.70 to $1.74 per share, above its previous guidance of $1.63 to $1.68 per share.
Separately, TheStreet Ratings team rates ZOETIS INC as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation:
We rate ZOETIS INC (ZTS) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and weak operating cash flow.
You can view the full analysis from the report here: ZTS
data by